News

Scientists have long believed that ALS was confined to one area of the brain, but an Irish study shows it affects a number of regions. Researchers at Trinity College Dublin’s Academic Unit of Neurology used electroencephalography, or EEG, to record patients’ brain activity. They discovered that nerve cell communication was lower…

Amyotrophic lateral sclerosis (ALS) patients with locked-in syndrome reported having a satisfactory quality of life and low levels of depression, in spite of their near-complete disability, in a small but recent study. The results of the questionaire-based study were presented by its lead author, Dorothée Lulé, at the 28th…

BrainStorm Cell Therapeutics released new data on potential biomarkers from its Phase 2 trial investigating NurOwn, the company’s cell therapy for amyotrophic lateral sclerosis (ALS), at the International Symposium on ALS/MND meeting held in Boston last week. Both these findings and an ongoing Phase 3 trial, now recruiting patients in…

Pivotal Phase 3 clinical trial results presented at this year’s 28th International Symposium on ALS/MND reveal that Cytokinetics‘ investigational therapy tirasemtiv failed to provide a positive therapeutic impact on both muscle strength and slow vital capacity (SVC) in ALS patients. The results, which were presented by Jeremy Shefner, MD,…

The rate of ALS patients’ lung-function decline can predict their risk of breathing failure, their need for assisted ventilation, and their risk of death, according to Cytokinetics, a company that develops muscle-disease therapies. “These results suggest that respiratory function is an important prognostic indicator of clinical progression in people with…

Additional data on Radicava (edaravone) and the clinical trial that led to its approval to treat amyotrophic lateral sclerosis (ALS) will be presented in oral and poster presentations at the 28th International Symposium on ALS/MND that opens in Boston on Friday. Mitsubishi Tanabe Pharma America announced that its one oral…

Using stem cell treatments to protect motor neurons is not enough to prevent the loss of nerve-muscle connections and disease progression in a mouse model of amyotrophic lateral sclerosis (ALS), researchers from Italy found. The study, published in the journal Stem Cell Research, had exposed mice to repeated brain…

Takeda Canada and the Montreal Neurological Institute (MNI) are teaming up to conduct joint research aimed at developing new therapies for amyotrophic lateral sclerosis (ALS). The collaborative effort includes developing and examining multiple cell assays from ALS patients over the next three years, from 2017 to 2020,…

https://vimeo.com/168979927 This short video from the ALS Association Texas Chapter shares the early symptoms of amyotrophic lateral sclerosis (ALS) using simple computer-generated animation. MORE: Discover seven facts about ALS you might find interesting ALS is difficult to diagnose in the early stages as the symptoms presented often mimic other diseases and conditions.

The U.S. Department of Veterans Affairs (VA) has added Radicava (edaravone) to its national formulary (VANF), making it possible for veterans with amyotrophic lateral sclerosis (ALS) to access treatment within the VA’s healthcare system, according to Mitsubishi Tanabe Pharma America (MTPA). The VANF is a list of drugs and…